308,809 Shares in OptimizeRx Corp. $OPRX Bought by CenterBook Partners LP

CenterBook Partners LP purchased a new position in OptimizeRx Corp. (NASDAQ:OPRX) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 308,809 shares of the company’s stock, valued at approximately $6,331,000.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of OptimizeRx by 15.0% in the third quarter. Vanguard Group Inc. now owns 1,059,109 shares of the company’s stock worth $21,712,000 after acquiring an additional 138,224 shares during the period. Manatuck Hill Partners LLC lifted its holdings in OptimizeRx by 139.5% in the 2nd quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company’s stock worth $6,142,000 after purchasing an additional 265,000 shares in the last quarter. Balyasny Asset Management L.P. bought a new position in OptimizeRx in the 2nd quarter worth approximately $2,111,000. Russell Investments Group Ltd. grew its holdings in OptimizeRx by 141.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 110,610 shares of the company’s stock valued at $1,493,000 after buying an additional 64,790 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in OptimizeRx during the 2nd quarter valued at approximately $1,141,000. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OPRX has been the topic of several research analyst reports. Wall Street Zen raised shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. Weiss Ratings reiterated a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday, December 22nd. Stephens dropped their price objective on shares of OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating for the company in a report on Monday, November 17th. Zacks Research cut OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Finally, Citizens Jmp increased their price target on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, OptimizeRx currently has a consensus rating of “Moderate Buy” and an average target price of $20.50.

OptimizeRx Stock Performance

Shares of NASDAQ:OPRX opened at $8.29 on Wednesday. The firm has a fifty day simple moving average of $11.94 and a two-hundred day simple moving average of $15.43. OptimizeRx Corp. has a 52 week low of $3.99 and a 52 week high of $22.25. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $154.53 million, a P/E ratio of 21.88 and a beta of 1.18.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.